Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Hepatitis C Drugs Market Global Forecast By Distribution Channels - Renub ResearchAccording to Renub Research analysis Global Hepatitis C Drugs Market would be US$ 5.9 Billion by 2025. Forecast By Regions & Distribution Channels
By: Renub Research In recent years, several drugs have been launched due to the high prevalence of Hepatitis C across the globe. Hepatitis C drug market is always developing, and competition is between new launches of fixed-dose combination led to a change in revenue of companies. The newly launched drug by AbbiVie i.e., Mavyret, has led to a downfall in the revenue of one of the market leader i.e. Gilead's. Mavyret has several advantages compared to other drugs such as its treatment course is shorter, and it is much cheaper. Harvoni drugs are popular in India, and it's easier affordable among the public. Oral injections and dosages are required weekly in Hepatitis C; at the same time, its side effects can lead to permanent damage of other organs of patients. Around the globe, many clinical trials, as well as numerous successful drug clearances, give traction to this market. Apart from that, the rising number of regulatory approvals will further boost the market during the forecast time frame. Hepatitis C drugs have witnessed numerous drug approvals likewise, in the year 2019, USFDA approves Mavyret for the treatment of pediatric hepatitis patients. For the treatment of all genotypes of Hepatitis C, Mavyret was the first treatment. Follow the link for more information: About Us: Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to- Contact Us Renub Research Phone: +1-678-302-0700 Email: info@renub.com End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|